Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin vs Sorafenib in PD-L1 Positive Advanced HCC
NCT03236649Phase 3Terminated
- Start
- Sep 2017
- Primary completion
- Feb 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of Icaritin in hepatocellular carcinoma (HCC). Started Sep 2017; status: terminated.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03236649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236649.